Lidocaine topical gel - Pharmanest

Drug Profile

Lidocaine topical gel - Pharmanest

Alternative Names: SHACT

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmanest
  • Class Acetanilides; Analgesics; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Procedural pain

Most Recent Events

  • 20 Nov 2017 Pharmanest and Gedeon Richter enter into a licensing agreement for the commercialisation of SHACT technology in Europe, Latin America and other specific geographies for the treatment of Procedural pain
  • 12 Oct 2017 Pharmanest plans a clinical development for Procedural pain in North America during 2018
  • 02 Sep 2015 Phase-II development for Procedural pain is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top